Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch
Amoneta Diagnostics is pleased to announce its’ team’s participation to the AD/PD™ 2025 conference, a major international event that brings together experts in the field of Alzheimer’s and Parkinson’s disease. This year, the focus will be on APO-Easy®, our CE-IVDR certified genotyping kit that is designed to assess genetic risk for Alzheimer’s disease through the analysis of the APOE gene. With the launch of groundbreaking new treatments for Alzheimer’s disease, the need for ident...
